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Abstract 
 
 
Purpose of review: Pharmaceutical cannabinoids such as nabiximols, nabilone and dronabinol, and 
plant-based cannabinoids have been investigated for their therapeutic potential in treating multiple 
sclerosis (MS) symptoms. This review of reviews aimed to synthesise findings from high-quality 
systematic reviews that examined the safety and effectiveness of cannabinoids in multiple sclerosis. 
We examined the outcomes of disability and disability progression, pain, spasticity, bladder function, 
tremor/ataxia, quality of life and adverse effects. 
 
Recent findings: We identified 11 eligible systematic reviews providing data from 32 studies, 
including 10 moderate- to high-quality RCTs. Five reviews concluded that there was sufficient 
evidence that cannabinoids may be effective for symptoms of pain and/or spasticity in MS. Few 
reviews reported conclusions for other symptoms.  
Summary: Recent high quality reviews find cannabinoids may have modest effects in MS for pain or 
spasticity. Future research should include studies with non-cannabinoid comparators is this an 
important gap in the evidence.  
 
 
Keywords 
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Introduction  
Multiple sclerosis is a chronic neuroinflammatory disease of the brain and central nervous system. It 
is characterized pathologically by demyelinating plaques within both grey and white matter, 
representing loss of both myelin sheath and supporting oligodendrocytes [1]. While remyelination 
may occur early in the history of the disease, over time this inflammatory process results in 
progressive neuroaxonal loss and increased disability.  
The course of the condition varies in clinical form, with relapsing-remitting multiple sclerosis 
(RRMS) accounting for approximately 85% of cases [2]. The varied signs and symptoms of multiple 
sclerosis depend upon the site of lesions in the brain and spinal cord. Common symptoms and signs 
include: spasticity, weakness, sensory disturbances, painful spasms, ataxia, tremor, optic neuritis and 
complex opthalmoplegias, fatigue and dysphagia [1]. There is considerable heterogeneity in the 
course of the disease and its symptoms [3] so treatment needs to be individualised to address the 
symptoms that patients report most adversely affect their quality of life [4].  
Current drug therapies for multiple sclerosis can be grouped into two categories: disease-modifying 
and symptomatic therapies. Disease-modifying therapies aim to lessen the number, severity and 
duration of relapses, maintain remission, and slow progression. These therapies are usually 
immunomodulatory and/or immunosuppressive treatments such as, interferon beta, copaxone, 
fingolimod, natalizumab and alemtuzumab [5-7]. Symptomatic therapies that relieve the distressing 
and/or disabling symptoms of multiple sclerosis include: anticonvulsants for neuropathic pain, 
anticholinergic drugs for bladder dysfunction and dysphagia, and botulinum toxin injections for 
spasticity [1]. The use of these symptomatic therapies may be limited by their toxicity [8]. 
Anecdotal reports that patients with multiple sclerosis experience symptomatic relief after smoking 
cannabis have prompted research using cannabinoids to manage symptoms [9]. Research is now also 
examining the potential for cannabinoids to slow disease progression as well as palliate spasticity and 
pain [10]. 
Neuropathic pain and pain in association with muscle spasms are common distressing symptoms in 
multiple sclerosis [11]. Animal models have suggested that cannabinoid (CB)-1 receptor activation 
may reduce neuropathic, visceral and inflammatory pain [12, 13]. Several preclinical studies have 
demonstrated that systemic administration of cannabinoid receptor ligands produce analgesia in acute 
and chronic pain models [14]. Research has also explored the role of CB2 receptors, which seem to 
mediate anti-hyperalgesia in inflammatory pain states, [15, 16] and reduce inflammation and 
neuropathic pain [17]. Cannabinoids, and the endocannabinoid system, have been demonstrated to 
have a role in reducing spasticity in animal models [18].  
Multiple reviews on this topic have been conducted with varying conclusions. This systematic review 
of reviews synthesises moderate to high quality reviews assessing the effectiveness of cannabis and 
cannabinoids for treating multiple sclerosis. More specifically, the objectives are to identify the 
effectiveness of plant based cannabinoids, and pharmaceutical cannabinoids (plant-derived or 
synthetically manufactured) in reducing disability and disability progression, pain, spasticity and 
improving quality of life in people with multiple sclerosis. These outcomes are patient-centred, short 
to medium term, and relevant to the daily lives and experiences of people living with multiple 
sclerosis. 
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Methods 
Inclusion criteria 
Types of participants 
The review considered systematic reviews of studies that included participants with multiple sclerosis. 
Types of intervention 
We included reviews of studies that evaluated plant-based and pharmaceutical cannabinoids: 
tetrahydrocannabinol; cannabidiol; combination tetrahydrocannabinol + cannabidiol; cannabis sativa; 
and where evidence exists, other cannabinoids e.g. tetrahydrocannabinolic acid (thca), cannabidiolic 
acid, cannabidivarin, and the synthetic delta-9-tetrahydrocannabinol formulations nabilone and 
dronabinol).  
Types of outcomes  
This review considered the following eight key outcomes in trials of cannabinoids for symptom relief 
in multiple sclerosis [19]: 
 Disability and disability progression 
 Pain 
 Spasticity 
 Bladder function  
 Ataxia and tremor 
 Sleep 
 Quality of life 
 Adverse effects 
Inclusion criteria 
We included reviews of experimental and epidemiological study designs. These included: randomised 
controlled trials, non-randomised controlled trials, quasi-experimental, before and after studies, 
prospective and retrospective cohort studies, case control studies and analytical cross sectional 
studies. Reviews were required to meet the minimum standards of describing a systematic search and 
providing study level data within the review (i.e. met the AMSTAR criteria 3 and 6, See Appendix 2). 
Review articles that were not published in English were considered for inclusion. Where these 
reviews used high quality methodology or provided research evidence that was not included in 
existing reviews we planned to obtain translations, however no such reviews were identified.  
Exclusion criteria 
We did not include reports of single studies, reviews of mechanisms of cannabinoid systems, or 
commentary articles and clinical overviews that did not describe a systematic review or assess and 
synthesise evidence at the individual study level.  
Search strategy 
Eight databases (Medline, Medline In-Process & Other Non-Indexed Citations /Ovid; Embase /Ovid; 
PsycINFO /Ovid; EBM Reviews- Cochrane Central Register of Controlled Trials / Ovid) were 
searched with the terms below (and their corresponding subject headings in each database where 
specialised thesauri existed). The searches were limited to studies published from 1980 to the end of 
2016. (A sample Medline search is reproduced Appendix 1). 
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Two reviewers independently examined titles and abstracts using Covidence Software. Relevant 
review articles were obtained in full, and independently assessed for inclusion in the review by two 
reviewers. Reasons for exclusion were documented in Covidence. Inter-reviewer disagreement was 
resolved by consensus in all cases. 
 
Assessment of methodological quality 
The full text reviews deemed eligible by two reviewers were assessed for quality by one reviewer and 
these quality ratings were checked by a second reviewer. Methodological quality ratings described the 
methodological quality across 11 pre-defined domains for each included review using the AMSTAR 
measurement tool to assess the methodological quality of systematic reviews [20] (Appendix 2). The 
AMSTAR tool documents assessed risk of bias at the review level.  
To be eligible for inclusion, a review needed to meet criteria 3 and 6 of the AMSTAR tool. These 
criteria required that a review described a comprehensive search and described the characteristics of 
the studies included in the review. Those studies that did not meet criteria 3 and 6 are listed in 
Supplementary Table 1 with the other excluded studies. Details of reported potential conflicts of 
interests of review authors were extracted (See Supplementary Table 3). Details of AMSTAR scores 
for individual items are also reported in Supplementary Table 3. 
Grading of evidence  
An evidence grade was given to each review using the Scottish Intercollegiate Guidelines Network 
(SIGN) grading system [21]. To enable an assessment of the evidence contained in the reviews, we 
also rated the individual studies included in the review according to the GRADE criteria [22]. Where 
reviews reported an assessment quality metric for each study, this was considered in the assessment. 
As per the GRADE rating, randomized controlled trials (RCTs) were considered high quality 
evidence, downgraded RCTs (for reasons of bias, sample size or other issues around design) were 
considered moderate quality evidence, double downgraded RCTs (e.g. downgraded two levels from 
high to low quality because of multiple concerns with study design or bias) or observational studies 
were considered low quality evidence, and triple downgraded RCTs, downgraded observational 
studies, case series or case studies were considered very low quality evidence (See Supplementary 
Table 4).  
 
Data collection 
Data were extracted from reviews using a standardized data extraction tool implemented in a 
custom-built Microsoft Access database. The data extracted included details about the interventions, 
populations, study methods and outcomes of interest. Data extraction tools were piloted and reviewed 
by the study authors before the results of the extraction were finalised.  
Data synthesis 
Review findings were synthesised to highlight when multiple reviews arrived at the same or different 
conclusions and to describe the strength of the evidence in each case. We synthesised findings by 
generating a set of statements that represented the findings according to their quality and the similarity 
in review conclusions.  
  
 Page 7 
Results 
 
Results are presented grouped by cannabinoid types. Where reviews did not identify studies that 
reported on outcomes measure for a specific cannabinoid product, the gaps in the evidence are also 
indicated in Table 2. 
Description of reviews 
Eleven reviews met the eligibility criteria (See Figure 1; Table 1). Two Cochrane reviews were 
identified that focused on ataxia and tremor [23] and spasticity [24]. The remaining nine systematic 
reviews focused on multiple sclerosis [25, 26], movement disorders more broadly [27-29], or included 
studies of multiple sclerosis as part of more comprehensive reviews of the therapeutic uses of 
cannabinoids [30-33]. 
Five reviews were graded as 1+ in the SIGN grading system. This represents ‘well-conducted 
meta-analyses, systematic reviews, or randomised control trials with a low risk of bias’. Six reviews 
had a SIGN grading of 1- comprising ‘meta-analyses, systematic reviews, or randomised control trials 
with a high risk of bias’. Quality as rated with the AMSTAR scale ranged from 2 to 10 out of a 
possible 11, with a mean score of 6. The reviews covered studies published between 1981 and 2013, 
and the reviews themselves were published between 2006 and 2016. The reviewed studies assessed a 
range of cannabinoids including tetrahydrocannabinol (THC), cannabidiol (CBD), THC:CBD 
formulations, pharmaceutical cannabinoids (dronabinol and nabilone), smoked cannabis sativa plant 
material and oral cannabinoid extracts (Table 2). 
Evidence was examined on eight pre-specified outcomes. Details by outcome domain are provided 
below. A summary of the review evidence on the eight outcomes is presented in Table 2. 
Quality of the evidence contained in the reviews 
Overall, 32 published reports were identified from the 11 systematic reviews. Of these, four provided 
very low quality evidence, 17 provided low quality evidence, 9 provided moderate quality evidence 
and two publications from one larger RCT (> 300 people) judged to have a low risk of bias provided 
high quality evidence (see Appendix 3).  
Disability and disability progression  
Six reviews reported data relating to disability or disease progression using different scales and 
outcome measures [24, 25, 29-31, 33] (See Supplementary Table 5). Overall, the effects of 
cannabinoids on disability and disease progression were mixed. Reviews did not report conclusions 
on this outcome, or focus on disability and disease progression as the primary outcome.  
Pain  
Seven reviews reported on a range of cannabinoids for the treatment of pain in patients with multiple 
sclerosis [24, 26, 28-31, 33] (See Supplementary Table 6). Although the effects were mixed, reviews 
presented evidence that most cannabinoids reduced pain on at least some measures.  
Two reviews of medium quality (AMSTAR score 4 and 5 out of 11) concluded that there was 
evidence that THC and THC:CBD/nabiximols were efficacious or probably efficacious in reducing 
pain or painful spasm in multiple sclerosis [28, 29]. Some reviews concluded that there was 
insufficient evidence or mixed findings [24, 26, 33]. One review cited a non-significant meta-analysis 
of 3 studies (565 participants) with a pooled effect size for cannabinoids of 0.08 (95 % CI: -0.74 to 
0.89) [26], though noted positive results were observed when only studies of central pain were 
considered. The highest quality review (AMSTAR score of 10) did not report conclusions for the 
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outcome of pain in multiple sclerosis, although it concluded that cannabinoids may reduce spasticity 
[30] which is associated with pain.  
Spasticity  
Seven reviews examined the effects of cannabinoids on spasticity in multiple sclerosis [24, 25, 28-31, 
33] (See Supplementary Table 7). Many reported outcomes on the Ashworth Score, a measure of 
spasticity on a 5-point scale using subjective clinical assessments of tone ranging from 0 – ‘no 
increases in tone’ to 4 – ‘limb rigid in flexion or extension [abduction/adduction]’ [34].  
In general, results were inconsistent between studies identified in the reviews, with many reporting 
positive effects on some, but not all measures of spasticity. Reviews reported that many studies did 
not find an effect of cannabinoids on spasticity using the Ashworth scale, one of the most widely used 
measures for this outcome. Positive effects were reported, however, on patient rated measures of 
spasticity. 
One review conducted a meta-analysis of outcomes of spasticity measured on the Ashworth scale 
[30]. This meta-analysis demonstrated a trend towards an improvement (reduced score on the 
Ashworth scale) but did not detect a statistically significant effect, either when cannabinoid types 
were examined alone, or when all studies were considered together. In a total of 1134 participants, the 
mean difference was –0.12 units on a five-point scale (95%CI –0.24 to 0.01)].  A meta-analysis of 
three studies found nabilone and nabiximols were associated with a greater average improvement on 
spasticity measured with a numerical rating scale (mean difference, -.76, [95%CI: -1.38 to -.014]). 
From these results, the authors concluded that there was moderate-quality evidence to suggest 
cannabinoids may reduce spasticity [30].  
Three other reviews also concluded favorably on the use of cannabinoids to treat spasticity. Ben Amar 
[33] concluded that cannabinoids objectively showed a small noticeable beneficial effect on spasticity, 
and Koppel et al. [28] concluded that THC:CBD extracts are effective, and THC/nabiximols are 
probably effective in treating painful spasticity. A similar conclusion was reached by Lakhan and 
Rowland [25] in their review of whole plant extracts. Karst et al [29] concluded there was evidence of 
efficacy but a narrow therapeutic index limiting use. Overall, most reviews found evidence that THC 
and THC:CBD products may reduce spasticity or concluded that it generally favoured cannabinoids to 
treat spasticity based on the results of individual studies or trends towards significant effects [25, 
28-30, 33]. 
Bladder function  
Four reviews considered evidence on the effects of cannabinoids on bladder function in multiple 
sclerosis [28, 29, 31, 33] (See Supplementary Table 8). In most of these reviews this was not the 
primary outcome, and few reviews reported conclusions on the clinical use of cannabinoids for this 
indication. One review concluded that there was evidence that THC:CBD oromucosal spray was 
probably effective, whereas oral cannabinoid extracts and THC were probably not effective in 
reducing bladder symptoms [28].  
In general, the reviews provided some evidence, including positive findings from high quality RCTs, 
that THC and THC:CBD had positive effects on bladder symptoms. The latter included fewer voids, 
reduced frequency of nocturia and improved incontinence-related quality of life measures. These 
effects were not consistently observed across studies in the reviews and positive findings from smaller 
studies were not confirmed in larger, high quality studies. 
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Ataxia and tremor  
Four reviews considered evidence on the effects of cannabinoids on ataxia and tremor with use of 
dronabinol, nabilone, nabixmols and THC:CBD extracts [23, 27, 28, 33] (See Supplementary Table 
9). In most reviews this was not a primary outcome so few reported on the clinical use of 
cannabinoids for this indication. One review concluded that THC and oral cannabinoid extracts were 
probably ineffective, and nabiximols were possibly ineffective for tremor [28]. A second review 
stated that no conclusions could be made of the efficacy of cannabinoids on the treatment of 
movement disorders, with studies failing to demonstrate a significant effect on tremor. [27].Studies 
identified in reviews were generally small and not likely to have had the power to detect anything but 
very large effects.  
Sleep  
Three reviews reported on the effects of cannabinoids on measures of sleep [29, 31, 33] (See 
Supplementary Table 10). Sleep was also not a primary outcome in any review and no review 
reported a conclusion on the clinical use of cannabinoids to improve sleep in people with multiple 
sclerosis.  
Quality of life 
Four reviews examined the effect of cannabinoids on overall quality of life or other measures of 
general functioning in patients with multiple sclerosis [23, 29, 30, 33] (See Supplementary Table 11). 
Reviews provided evidence of mixed findings on the effect of cannabinoids on quality of life, with 
reviews reporting data from studies that found both positive and negative effects on quality of life. 
One review reported that cannabinoids can lead to a moderate improvement in general well-being 
[33]. 
Adverse effects 
Eight reviews reported data on adverse effects (AEs) of cannabinoids in treating multiple sclerosis 
[25, 26, 28-33] (See Supplementary Table 12). This included one systematic review of the adverse 
effects of therapeutic cannabinoids, from which we extracted data on studies in patients with multiple 
sclerosis [32].  
 
Most reviews identified similar AEs from cannabinoids that were most frequently described as ‘mild’ 
to ‘moderate’. They included: dizziness, dry mouth, euphoria, diarrhoea, and difficulty concentrating. 
Adverse effects were consistently rated as more common in study participants who received 
cannabinoids than placebo. Most reviews did not draw conclusions on whether any of these adverse 
effects precluded clinical use.  
 
No specific cannabinoid was identified as having a more serious adverse effect profile than another. 
Whiting et al. [30] noted that no cannabinoid or route of administration was associated with any 
specific adverse event. Their meta-analyses of adverse events over a range of cannabinoids and 
medical conditions found that an adverse event was around three times more likely to occur with a 
cannabinoid than placebo (OR 3.03, 95%CI 2.42-3.80). There was a slightly greater odds of a serious 
adverse event (OR 1.41, 95%CI 1.04-1.92), and three times the odds of patients withdrawing due to 
adverse events with patients receiving cannabinoids rather than placebo (OR 2.94, 95%CI 2.18-3.96). 
They noted the lack of long-term follow up data on adverse events. 
 
Karst et al. [29] concluded that the risk to benefit profile was not optimally balanced with existing 
cannabinoid products. Koppel et al [31] noted that adverse effects were a concern in patients with 
multiple sclerosis. One specific concern raised was the potential cognitive impairing effects of 
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cannabinoids in patients with pre-existing cognitive dysfunction [28]. Other reviews expressed 
caution about use of cannabinoids in the elderly and persons with a psychosis [33].  
 
Review findings were inconsistent on the effect of the addition of CBD to THC on the adverse effect 
profile of THC. Some reviews identified evidence of an attenuation of adverse effects related to THC, 
while other reviews identified greater adverse effects from THC:CBD combinations than THC [25, 
31]. Adverse effects with oral THC/dronabinol were dose dependent. One review identified that at 
least 10mg of THC was reported as required to reduce spasticity and adverse effects were observed 
with doses of 15mg and above [29]. Reviews were not able to compare side effects of cannabinoids 
with those of other active treatments because of a lack such studies.  
 
General conclusions of the reviews  
One recent high-quality review [30] concluded that there was sufficient evidence to support the 
clinical use of nabiximols, nabilone, THC/CBD capsules, and dronabinol in treating symptoms of 
multiple sclerosis (See Supplementary Table 13). This review received an AMSTAR score of 10 and 
reported on 7 studies in patients with multiple sclerosis involving a total of 1218 participants.  
 
Four other reviews similarly concluded that there possibly or probably beneficial effects on some 
outcomes (such as pain, spasticity and bladder symptoms) [25, 28, 29, 33]. A further four reviews 
concluded that there was insufficient evidence to make any recommendations [23, 24, 27, 31]. The 
scope of these latter reviews was often narrower (e.g. limited to a specific symptom such as ataxia, or 
to a specific cannabinoid, such as cannabidiol). One review was focused on adverse effects as 
opposed to clinical efficacy [32].   
 
No reviews made a recommendation on where cannabinoids would fit in the therapeutic hierarchy in 
treating different symptoms of multiple sclerosis, i.e. whether cannabinoids should be used as first 
line or later line treatments only after other treatments had been tried. No review recommended their 
use as a monotherapy.  
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Discussion   
We reviewed the findings of 11 systematic reviews of evidence on the potential benefits of 
cannabinoids for multiple sclerosis. Recent high-quality reviews supported the clinical use of 
cannabinoids for spasticity and pain in multiple sclerosis. The findings were inconclusive on use to 
treat other common symptoms (e.g. bladder control, ataxia and tremor). Some positive findings appear 
to support clinical use of cannabinoids in spasticity, although the magnitude of the effect was 
generally small. Few reviews could conduct meta-analyses because the measures used and outcomes 
examined were not standardized.  
Reviews identified potentially negative effects in a small number of studies, often of low quality. A 
potential negative effect of cannabinoid use on disease progression warrants further research 
especially as many of the positive studies only measured short-term outcomes (i.e. up to twelve 
weeks). 
Beneficial effects on bladder function and sleep were identified by some reviews. Because these 
symptoms were rarely the primary focuses of reviews, no reviews offered clinical recommendations 
on the use of cannabinoids for these indications. Future research may evaluate the effects of 
cannabinoids in patients who report that these are their symptom of greatest concern. 
One challenge in studying the effects of cannabinoids on multiple sclerosis is that patients have 
heterogeneous symptom profiles. This may make it difficult to find an effect on secondary outcome 
measures when symptoms are not found in all study participants. The seriousness of adverse effects 
may also vary with patients’ presenting symptoms. For example, those with cognitive impairment 
may be more susceptible to potential cognitive effects of cannabinoids [28].  
A further challenge identified in the systematic reviews was a lack of harmonisation across the studies 
in the outcome measures used. This makes synthesis of findings challenging. Finally, the cannabinoid 
products evaluated were considered suboptimal. Newer cannabis products may have different 
risk-benefit profiles. 
There are some limitations with the current review. Some of the evidence considered in the reviews 
came from well-conducted RCTs, including some with large samples sizes. This was supplemented by 
weaker evidence from studies with smaller sample sizes and subject to possible biases from weak 
study design. Different reviews reported on different outcome measures relating to symptoms of 
multiple sclerosis. In some cases this explained why reviews came to different conclusions on the 
efficacy of cannabinoids despite including the same studies.  
Some reviews argued that the risk versus benefit decision for patients with multiple sclerosis may 
need to be made at the individual rather than the population level. Their use may depend on which 
symptoms are most problematic for the patient, and on how the adverse effects of cannabinoids affect 
their quality of life. Most adverse events and most benefits reported in systematic reviews are likely to 
be noted within a short period of time. This facilitates individualised decision making by means of a 
time-limited therapeutic trial. One study reported that benefits of cannabinoids are generally observed 
in the first four weeks of the study [35]. If so, a trial of 4-6 weeks may enable patients and their 
physicians to assess whether their symptoms will respond to cannabinoids. If benefits are not 
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observed in this time, there is little benefit expected from continued use [35].  
Few reviews drew any conclusions on use with symptoms other than pain or spasticity and some 
which reported benefits in spasticity found detriments in other domains, complicating general 
statements about the risk/benefit ratio of cannabinoids for individuals. 
Further research 
One area in which further research is required is the possible role of cannabidiol in disease 
progression. One reviews reported that the THC:CBD combination may have adverse effects and 
showed more disease progression compared with THC alone [31]. Further, few studies used active 
comparators, and no review commented on if cannabinoids could be considered as a monotherapy. 
Given that there are other treatments with considerable efficacy for multiple sclerosis, studies with 
active comparators will be critical in further informing clinical decision making about the use of 
cannabinoids.   
Conclusions 
In conclusion, reviews identified evidence that would support a trial of cannabinoids for pain or 
spasticity in a patient with multiple sclerosis. Effect sizes are generally small suggested only modest 
effects may be expected. Adverse events were generally mild to moderate, although caution is 
warranted in specific populations of patients with multiple sclerosis with greater vulnerability to 
adverse effects from cannabinoids.    
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Figure 1. PRISMA Flow Diagram for selection of reviews 
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Table 1. Overview of reviews characteristics 
Review ID Title Type of 
review 
Aim of review Types of evidence considered by the review, and sample size reported^ (^note 
that reported sample size differed for the same study between reviews) 
Year 
studies 
published  
SIGN 
Grade 
Funding/COIs AMSTAR 
Score 
Andrzejewski 
2016 
Cannabinoids in the 
treatment of movement 
disorders: A systematic 
review of case series and 
clinical trials 
Systematic 
review 
To assess the use of 
exogenous cannabinoids in 
the treatment of movement 
disorders  
Two randomised, double-blind placebo controlled crossover study (n =14[Fox 2004] 
and n = 57 [Vaney 2004].), one case series (n = 8 [Clifford 1983]), one randomised 
double blind parallel group (1, n = 337 Collin 2010) and one double blind RCT (1, n = 
667 Wade 2004) 
2003-2010 1- Not reported 2 
Whiting 2015 Cannabinoids for medical 
use: a systematic review 
and meta-analysis 
Systematic 
review 
To conduct a systematic 
review of the benefits and 
adverse events of 
cannabinoids. 
Parallel RCT (Collin 2007 [n = 189], Collin 2010 [ n = 337], Langford 2013 [n = 339], 
Van Amerongen 2014 [n = 24] , Wade 2004 [n = 160], Zajicek 2003 [n = 657], Zajicek 
2012 [n = 279]) or crossover RCT (Corey-Bloom 2012 [n = 37], Killestein 2002 [n = 
16], Leocani 2014 [n = 43], Vaney 2004 [n = 57]). 
2003-2010 1+ Declared 
funding/no 
apparent COI 
10 
Koppel 2014 Systematic review: efficacy 
and safety of medical 
marijuana in selected 
neurologic disorders 
Systematic 
review 
To determine the efficacy of 
medical marijuana in several 
neurologic conditions 
Double blind RCTs (Kavia 2010 [n = 135], Zajicek 2003 [n = 630], Wade 2004 [n = 
160], Vaney 2004 [n = 57], Freeman 2006 [n = 522], Zajicek 2012 [ n = 224], Rog 2005 
[n = 66], Collin 2010 [n = 265], Zajicek 2005 [n = 502],  Corey-Bloom [n = 37], 
Svendsen 2004 [n = 24],  Greenberg 1994 [n = 20]), Killestein 2002 [n = 16], Collin 
2010 [ n = 337], Fox 2004 [n = 14], Fox 2002 [n = 15]) Randomised double-blind 
controlled trial (Ungerleider 1987 [n = 13]); Open label study (Centzone 2009 [n = 
20]), Open label follow-up post RCT (Wade 2006 [n = 137]). 
1987-2012 1- Declared 
funding with 
no apparent 
COI 
4 
Jawahar 2013 A systematic review of 
pharmacological pain 
management in MS 
Systematic 
review 
To systematically review pain 
management strategies for the 
reduction of non-spastic and 
non-trigeminal neuralgic pain 
in MS patients. 
Double blind placebo controlled RCTs ( Rog 2005 [n = 66], Wade 2004 [n = 160], 
Double blind crossover RCT (Svendsen 2004 [n = 24]). 
2004-2013 1+ No funding/ 
possible COI 
6 
Zhornitsky 
2012 
Cannabidiol in humans - 
The quest for therapeutic 
targets 
Systematic 
review 
To examine the randomized 
and crossover studies that 
administered CBD to healthy 
controls and clinical patients 
Clinical trials: Killestein 2002 (n = 16), Zajicek 2003 [n = 630], Freeman 2005 (n = 
255), Brady 2005 (n = 15) Wade 2003 (n = 20), Notcutt 2004 (n = 34),  
2002-2006 1- Not 
reported/no 
apparent COI 
3 
Karst 2010 Role of cannabinoids in the 
treatment of pain and 
(painful) spasticity 
Systematic 
review 
To review the most current 
and relevant data available on 
the antinociceptive properties 
of cannabinoids for their 
potential or already 
established use in clinical 
settings. 
For the clinical trials, we included non-randomized, observational, and randomized, 
double-blind, placebo-controlled trials (RCTs) in clinical and experimental settings. 
RCT: Petro and Ellenberger 1981 (n = 9), Ungerleider 1987 (n = 13), Martyn 1995 (n = 
1), Killestein 2002 (n = 16), Zajicek 2003 (n = 630), Wade 2003 (n = 24), Wade 2004 
(n = 160), Svendsen 2004 (n = 24), Vaney 2004 (n = 57), Zajicek 2005 (n = 502), Rog 
2005 (n = 66), Wade 2006 (n = 13), Rog 2007 (n = 63), Collin 2007 (n = 189), Conte 
2009 (n = 18), Centzone 2009 (n = 20), Collin 2010 (n = 337). 
1981-2009 1- No  funding 5 
Mills 2007 Treatment for ataxia in 
multiple sclerosis 
Cochrane 
review 
To assess the efficacy and 
tolerability of both 
pharmacological and 
non-pharmacologic 
treatments of ataxia and 
tremor in patients with MS. 
Blinded, randomised trials (RCTs), which were placebo-controlled or compared two or 
more treatments were included. One parallel (Wade 2004, [n = 160]) and two crossover 
studies (Fox 2004 [n = 14], Killestein 2002 [n = 16]) were reviewed. 
2002-2004 1- Not reported 9 
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Review ID Title Type of 
review 
Aim of review Types of evidence considered by the review, and sample size reported^ (^note 
that reported sample size differed for the same study between reviews) 
Year 
studies 
published  
SIGN 
Grade 
Funding/COIs AMSTAR 
Score 
Lakhan 2009 Whole plant cannabis 
extracts in the treatment of 
spasticity in M: a systematic 
review 
Systematic 
review 
To systematically evaluate the 
effectiveness of combined 
THC and CBD extracts on 
MS-related spasticity in order 
to increase understanding of 
the treatment's potential 
effectiveness, safety and 
limitations. 
Only randomized, placebo-controlled, human studies of 
shorter treatment periods (under 6 months) were 
included. Crossover RCT (Killestein 2002 [n = 16], Wade 2003 [n = 24], Vaney 2004 
[n = 57], Parallel RCT(Zajicek 2003 [n = 395], Collin 2007 [n = 184], Wade 2004 [n = 
154]) 
2002-2007 1+ No funding 7 
Shakespeare 
2003 
Anti-spasticity agents for 
multiple sclerosis 
Cochrane 
review 
To assess the absolute and 
comparative efficacy and 
tolerability of anti- spasticity 
agents in MS patients. 
Double-blind, randomised controlled trials (RCTs) of treatment 
duration longer than seven days which are either placebo-controlled 
or comparing two or more agents were analysed. Killestein 2002 [n = 16] reported a 
crossover study, Wade 2003 reported a crossover study [n = 160] 
2002-2003 1+ Not reported 9 
Wang 2008 Adverse effects of medical 
cannabinoids: a systematic 
review 
Systematic 
review 
To create an evidence base for 
cannabis-related adverse 
events and to facilitate future 
cannabis research initiatives. 
Randomized controlled trials evaluating the safety and efficacy of cannabis if adverse 
events were quantified. Observational studies in which cannabis represented the main 
exposure were included, provided the outcome of interest was adverse events. Case 
reports were included if they described adverse events in people exposed to cannabis. 
Studies on MS: Parallel RCTs (Collins 2007 [n = 189], Rog 2005 [n = 66], Wade 2004 
[n = 160], Zajicek 2003 [n = 630, Zajicek 2005 [n = 611] and Crossover RCT (Wade 
2003 [n = 611], Killestein 2002 [n = 16], Petro and Ellenberger 1981 [n = 9],  
Svendsen 2004 [n = 24], Vaney 2004 [n = 57]). 
1981-2007 1+ Funding not 
reported, 
author MW 
possible COI 
(speaker fees 
&consultancy) 
6 
Ben Amar 
2006 
Cannabinoids in medicine: 
a review of their therapeutic 
potential 
Systematic 
review 
To report on the most current 
data available on the 
therapeutic potential of 
cannabinoids. 
Double-blind Crossover RCT (Petro and Ellenberger 1981 [n = 9], Ungerleider 1987 [n 
= 13], Martyn 1995 [n=1], Killestein 2002 [n = 16], Wade 2003 [n = 18], Fox 2004 [n = 
14], Vaney 2004 [n = 50]) Single-blind placebo controlled (Clifford 1983 [n = 8], 
Double blind parallel RCT (Greenberg 1994 [n = 10], Zajicek 2003 [n = 630], Wade 
2004 [n = 160], Svendsen 2004 [n = 24]). 
1981-2004 1- Not reported 2 
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Table 2. Summary of study level evidence on the safety and efficacy of cannabis and cannabinoids in the treatment of multiple sclerosis 
 Disability and 
disease progression 
Pain Spasticity Bladder function Ataxia and tremor Sleep Quality of life Adverse events 
Cannabis sativa (smoked) 1 study (1 RCT) 1 study (1 RCT) 2 studies (2 RCT) No studies No studies No studies 2 studies (2 RCT) 2 studies (2 RCT) 
 Findings No change Positive effect Positive effect    Mixed effect AEs > comparator 
 Quality of evidence Low quality Low quality Low quality    Low quality Low quality 
 Conclusion 
Insufficient 
evidence 
Insufficient evidence Insufficient evidence    Insufficient evidence Insufficient evidence 
Dronabinol 4 studies (2 RCT) 4 studies (3 RCT) 5 studies (5 RCT) 2 studies (1 RCT) 3 studies (2 RCT) 2 studies (1 RCT) 2 studies (2 RCT) 8 studies (6 RCT) 
 Findings 
No change/negative 
effect 
Positive effect Mixed effect Mixed effect No change 
Mixed effect (mostly 
positive) 
Mixed effect AEs > comparator 
 Quality of evidence Very low to high Low to high quality Low to high quality High quality 
Very low to high 
quality 
Moderate to high 
quality 
Low to high quality 
Very low to high 
quality 
 Conclusion 
Inconsistent 
evidence 
Some evidence of 
positive effect 
Inconsistent evidence Inconsistent evidence 
Unlikely to have an 
effect 
Insufficient evidence Insufficient evidence Mild AEs likely 
THC extract No studies 3 studies (2 RCT) 2 studies (1 RCT) 1 study (No RCT) No studies 3 studies (2 RCT) No studies 1 studies (1 RCT) 
 Findings  Positive effect Positive effect Positive effect  Mixed effect  AEs > comparator 
 Quality of evidence  Very low to low 
Very low to low 
quality 
Very low quality  
Very low to low 
quality 
 Low quality 
 Conclusion  
Some evidence of 
effect 
Insufficient evidence Insufficient evidence  Insufficient evidence  Mild AEs likely 
Nabiximols 2 studies (2 RCT) 8 studies (5 RCT) 7 studies (6 RCT) 2 studies (2 RCT) 2 studies (2 RCT) 1 study (1 RCT) 5 studies (5 RCT) 10 studies (7 RCT) 
 Findings No change Mixed effect Mixed effect Mixed effect No change Positive effect Mixed findings AEs > comparator 
 Quality of evidence Moderate quality 
Very low to moderate 
quality 
Very low to moderate 
quality 
Moderate quality Moderate quality Moderate quality Moderate quality 
Very low to moderate 
quality 
 Conclusion 
Insufficient 
evidence 
Inconsistent evidence Inconsistent evidence Insufficient evidence 
Unlikely to have an 
effect 
Insufficient evidence 
Some evidence of 
positive effect 
Mild AEs likely 
THC:CBD extracts 6 studies (5 RCT) 7 studies (5 RCT) 6 studies (5 RCT) 4 studies (2 RCT) 4 studies (4 RCT) 4 studies (3 RCT) 3 studies (3 RCT) 8 studies (6 RCT) 
 Findings Mixed effect Mixed findings Mixed findings Mixed findings No change Mostly positive effect Mixed findings AEs > comparator 
 Quality of evidence Low to high quality 
Very low to high 
quality 
Low to high quality 
Very low to high 
quality 
Low to high quality Low to high quality Low to high quality Low to high quality 
 Conclusion 
Inconsistent 
evidence 
Inconsistent evidence Inconsistent evidence Inconsistent evidence 
Unlikely to have an 
effect 
Some evidence of 
effect 
Inconsistent evidence Mild AEs likely 
Nabilone No studies 1 study (1 RCT) 2 studies (2 RCT) 1 study (1 RCT) 1 study (1 RCT) No studies 2 studies (2 RCT) 3 studies (3 RCT) 
 Findings  Positive effect Positive effect Positive effect No change  Mixed effect AEs > comparator 
 Quality of evidence  Very low 
Very low to low 
quality 
Very low quality Low quality  
Very low to moderate 
quality 
Very low to low 
quality 
 Conclusion  Insufficient evidence Insufficient evidence Insufficient evidence Insufficient evidence  Insufficient evidence Mild AEs likely 
CBD extract No studies 2 studies (2 RCT) 1 study (1 RCT) No studies No studies 1 study (1 RCT) No studies 1 study (1 RCT) 
 Findings  Mixed effect Mixed findings   Positive effect  AEs > comparator 
 Quality of evidence  Low quality Low quality   Low quality  Low quality 
 Conclusion  Insufficient evidence Insufficient evidence   Insufficient evidence  Insufficient evidence 
Quality rating (Per GRADE approach in Cochrane Handbook V5.1) 
High: Randomized trials; or double-upgraded observational studies. 
Moderate Downgraded randomized trials; or upgraded observational studies. 
Low: Double-downgraded randomized trials; or observational studies. 
Very Low: Triple-downgraded randomized trials; or downgraded observational studies; or case series/case reports. 
 
